4 completed, 2 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Narcan: new trials by email Literature Review of Narcan trials Research Report on Narcan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg Nalmefene HCl injection, Naloxone HCl intranasal - Opioid Overdose | Phase 1 | Completed | Purdue Pharma LP | 24 | 2022-10-03 | 2025-07-03 |
| A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Nasus Pharma FMXIN001, Nasal Naloxone liquid spray - Opioid Overdose | Phase 1 | Completed | Nasus Pharma | 46 | 2021-01-31 | 2022-05-02 |
| The Effect of Chronic Pain on Delay Discounting in Methadone Patients Naloxone Hydrochloride, Placebo - Opioid-use Disorder, Chronic Pain Syndrome | Phase 1 | Terminated | University of California, San Francisco | 10 | 2020-01-08 | 2025-03-26 |
| Comparison of Naloxone Pharmacokinetics Naloxone, Mucosal atomization device and syringe, Narcan - Opioid-use Disorder | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 30 | 2018-01-03 | 2018-03-09 |
| Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia intra-nasal naloxone, Intra-nasal saline - Hypoglycemia Unawareness, Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | University of Minnesota | 11 | 2016-06-01 | 2023-03-27 |
| Evaluation of Intranasal Naltrexone and Naloxone Naltrexone, Naloxone, Naltrexol - Opioid-use Disorder | Phase 1 | Completed | National Institute on Drug Abuse (NIDA) | 12 | 2015-10-05 | 2020-09-14 |
Opioid-Related Disorders (3) · Opiate Overdose (2) · Diabetes Mellitus, Type 1 (1) · Hypoglycemia (1) · Impulsive Behavior (1)
National Institute on Drug Abuse (NIDA) (2) · Nasus Pharma (1) · Purdue Pharma LP (1) · University of California, San Francisco (1) · University of Minnesota (1)
United States (4) · Canada (1)
Amir Moheet, MD (1) · D. Andrew Tompkins, MD (1) · Debra Kelsh, MD (1) · Janice Faulknor, MD, CCFP (1) · Nora Chiang, PhD (1)
R21DA047520 (1)